Brind.

Edwards Lifesciences develops products designed to treat advanced cardiovascular diseases.

Steady: 1 in the last 7 days Updated friday

The latest in this situation

  1. The FDA approved Edwards' PASCAL Precision system, which is the sole provider of these therapies in the US.

How it started

2 reports, 2 independent, last reported Sep 2. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Edwards Lifesciences develops products designed to treat advanced cardiovascular diseases.

Who's involved

What this event is mainly about
Edwards Lifesciences

How it developed

Newest first. Tap a step to see who reported it.
  1. The FDA approved Edwards' PASCAL Precision system, which is the sole provider of these therapies in the US.Sub-event
  2. Edwards Lifesciences updated guidelines on August 29, 2025, simplifying care pathways and showing EVOQUE's superior clinical benefit.Sub-event
  3. Edwards Lifesciences focuses on developing products for advanced cardiovascular diseases.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • BarchartEdwards Lifesciences Stock: Is EW Outperforming the Healthcare Sector? Valued at approximately $47.8 billion by market capitalization, California-based Edwards Lifesciences Corporation (EW) develops
  • Medical Device NetworkESC 2025: Structural heart disease guidelines updated following Edwards trial results The European Society of Cardiology (ESC) has updated its care guidelines for valvular heart disease, due in large